MOTS-c调节ROS/TXNIP/NLRP3通路,以缓解糖尿病心肌病
Yu Fu1, Mi Tang2, Yimei Duan3
1School of Sports Medicine and Health, Chengdu Sport University, Chengdu, China.
Biochemical and biophysical research communications
|December 1, 2024
概括
线粒体衍生MOTS-c可以减少糖尿病患者心脏的炎症和损伤. 这种抑制ROS/TXNIP/NLRP3通路,为治疗糖尿病心血管并发症提供了潜力.
科学领域:
- 心血管生物学 心血管生物学
- 代谢疾病 代谢疾病
- 线粒体医学 线粒体医学
背景情况:
- 糖尿病的特点是慢性低度炎症,增加心血管事件的风险.
- 心肌损伤是糖尿病的常见并发症,导致严重的心脏问题.
- 线粒体衍生MOTS-c在调节新陈代谢和改善胰岛素抵抗方面显示出有前途.
研究的目的:
- 研究MOTS-c对糖尿病大鼠模型中的心脏结构和炎症的治疗效果.
- 阐明MOTS-c对糖尿病心肌病的保护作用背后的分子机制.
主要方法:
- 通过高糖脂肪饮食和链毒素诱导的糖尿病老鼠模型.
- 用MOTS-c (0.5毫克/公斤/天) 治疗8周.
- 对活性氧物种 (ROS),TXNIP和NLRP3炎症途径蛋白质的分析.
主要成果:
- 糖尿病大鼠的高葡萄糖水平激活了NLRP3炎症酶并增加了ROS,导致心肌损伤.
- MOTS-c治疗显著降低了ROS/TXNIP/NLRP3通路蛋白质表达.
- MOTS-c抑制了糖尿病心肌炎症反应,并减轻了心脏损伤.
结论:
- 在糖尿病老鼠中,MOTS-c有效缓解心肌损伤.
- MOTS-c的保护作用通过抑制ROS/TXNIP/NLRP3炎症通路进行介导.
- MOTS-c代表了糖尿病心血管并发症的潜在治疗剂.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386